Imexpharm Corporation (HOSE:IMP)

Market Cap	7.60T
Revenue (ttm)	2.31T
Net Income (ttm)	309.16B
Shares Out	154.01M
EPS (ttm)	2,007.45
PE Ratio	24.58
Forward PE	n/a
Dividend	454.55 (0.92%)
Ex-Dividend Date	Jul 11, 2024

Volume	268,459
Average Volume	125,923
Open	50,000
Previous Close	49,300
Day's Range	48,950 - 50,000
52-Week Range	29,636 - 56,500
Beta	0.69
RSI	69.49
Earnings Date	Apr 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 16.85%.